Evidence map›Paper›PMID 41689635›Full record

ReviewJournal of neurology2026

A roadmap for a patient-centred approach to Pompe disease management.

Benedikt Schoser, Cristina Domínguez-González, Pascal Laforet, Andreas Hahn, Paul Gissen, Anna Kostera-Pruszczyk, Andreas Thalmeier, John Vissing

Abstract readReview
In one paragraph

Review in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benedikt SchoserDepartment of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany. benedikt.schoser@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-2757-8131
Cristina Domínguez-GonzálezHospital Universitario 12 de Octubre, imas12 Research Institute, Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0001-5151-988X
Pascal LaforetNeurology Department, Raymond-Poincaré Hospital, AP-HP, Nord-Est-Île-de-France Neuromuscular Reference Center, Garches, France.ORCID http://orcid.org/0000-0001-8509-9107
Andreas HahnDepartment of Pediatric Neurology, Justus-Liebig University, Giessen, Germany.ORCID http://orcid.org/0000-0003-0235-5211
Paul GissenNational Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK.ORCID http://orcid.org/0000-0002-9712-6122
Anna Kostera-PruszczykDepartment of Neurology, Medical University of Warsaw, ERN EURO NMD, Warsaw, Poland.ORCID http://orcid.org/0000-0002-7309-1914
Andreas ThalmeierPharmacy, LMU-Klinikum, Munich, Germany.ORCID http://orcid.org/0009-0009-5455-5603
John VissingCopenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-6144-8544

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPompe disease is a rare, progressive genetic disorder caused by pathogenic variants in the GAA gene. Emerging gene therapies offer the potential for long-term disease management, although logistical and clinical challenges demand specialised centres with defined protocols. A scientific steering committee of 8 European experts deliberated on the requirements for establishing gene therapy centres of excellence for Pompe disease.

methodsA modified think-tank approach was used to develop expert-based recommendations through qualitative research utilizing expert opinion methodology. Discussion topics were validated in an online kick-off meeting. Experts were assigned specific topics and tasked with generating content. Multiple online meetings facilitated expert presentations, discussions, and validation of recommendations for each topic.

resultsOptimised patient management and timely access to treatment require accurate diagnosis and evaluation of Pompe disease. The committee recommended expanding newborn screening programs for infantile-onset Pompe disease and developing protocols for follow-up of presymptomatic late-onset Pompe disease. A specialised multidisciplinary team trained in Pompe disease and gene therapy should manage the patient journey. Pre-gene therapy assessments were recommended to mitigate risks. Patients should be hospitalized and continuously monitored during gene therapy infusions. After gene therapy, guidelines recommend corticosteroid immunosuppression, monitoring for adverse events (including hepatoxicity, myocarditis, thrombocytopenia, thrombotic microangiopathy, and hemophagocytic lymphohistiocytosis), and Pompe disease assessments (including motor functional assessments, magnetic resonance imaging of the muscles, and patient-reported outcomes). Centres of excellence require infrastructure with standard operating procedures for gene therapy products.

conclusionsImplementing gene therapy for Pompe disease requires a coordinated multidisciplinary effort to overcome gaps in knowledge, infrastructure, and patient management.

Indexed as

Disease ManagementGenetic TherapyGlycogen Storage Disease Type IIPatient-Centered CareHumansCentres of excellenceGene therapyMultidisciplinary teamPompe diseaseRare genetic disorderThink-tank methodology

Identifiers

PMID41689635
PMCPMC12906549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.